According to the Zhitong Finance App, Dongbao Biotech (300239.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 975 million yuan, an increase of 3.30% over the previous year. Achieved net profit attributable to shareholders of listed companies of 120 million yuan, an increase of 9.55% over the previous year. Achieved net profit of 110 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 9.08% over the previous year. Basic earnings per share were $0.202. It is proposed to distribute a cash dividend of 0.22 yuan (tax included) for every 10 shares to all shareholders.